248 related articles for article (PubMed ID: 17485307)
1. Epigenetics of prostate cancer.
Li LC
Front Biosci; 2007 May; 12():3377-97. PubMed ID: 17485307
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
Li LC; Carroll PR; Dahiya R
J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic modifications in prostate cancer.
Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
[TBL] [Abstract][Full Text] [Related]
4. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic targets in the diagnosis and treatment of prostate cancer.
Manoharan M; Ramachandran K; Soloway MS; Singal R
Int Braz J Urol; 2007; 33(1):11-8. PubMed ID: 17335593
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic biomarkers in prostate cancer: Current and future uses.
Chiam K; Ricciardelli C; Bianco-Miotto T
Cancer Lett; 2014 Jan; 342(2):248-56. PubMed ID: 22391123
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Regulation of Chromatin in Prostate Cancer.
Natesan R; Aras S; Effron SS; Asangani IA
Adv Exp Med Biol; 2019; 1210():379-407. PubMed ID: 31900918
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modifications in prostate cancer.
Sugiura M; Sato H; Kanesaka M; Imamura Y; Sakamoto S; Ichikawa T; Kaneda A
Int J Urol; 2021 Feb; 28(2):140-149. PubMed ID: 33111429
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation and histone modifications as epigenetic regulation in prostate cancer (Review).
Nowacka-Zawisza M; Wiśnik E
Oncol Rep; 2017 Nov; 38(5):2587-2596. PubMed ID: 29048620
[TBL] [Abstract][Full Text] [Related]
10. [Epigenetics of prostate cancer].
Yi XM; Zhou WQ
Zhonghua Nan Ke Xue; 2010 Jul; 16(7):635-41. PubMed ID: 20873600
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics in bladder cancer.
Enokida H; Nakagawa M
Int J Clin Oncol; 2008 Aug; 13(4):298-307. PubMed ID: 18704629
[TBL] [Abstract][Full Text] [Related]
12. SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms.
García-Tobilla P; Solórzano SR; Salido-Guadarrama I; González-Covarrubias V; Morales-Montor G; Díaz-Otañez CE; Rodríguez-Dorantes M
Gene; 2016 Nov; 593(2):292-301. PubMed ID: 27570179
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation in prostate cancer.
Li LC; Okino ST; Dahiya R
Biochim Biophys Acta; 2004 Sep; 1704(2):87-102. PubMed ID: 15363862
[TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications.
Yegnasubramanian S; De Marzo AM; Nelson WG
Cold Spring Harb Perspect Med; 2019 Apr; 9(4):. PubMed ID: 29959132
[TBL] [Abstract][Full Text] [Related]
15. Epigenetics in prostate cancer: biologic and clinical relevance.
Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Modifications and Modulators in Prostate Cancer.
Cimadamore A; Gasparrini S; Scarpelli M; Doria A; Mazzucchelli R; Massari F; Cheng L; Lopez-Beltran A; Montironi R
Crit Rev Oncog; 2017; 22(5-6):439-450. PubMed ID: 29604923
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic modulators as therapeutic targets in prostate cancer.
Graça I; Pereira-Silva E; Henrique R; Packham G; Crabb SJ; Jerónimo C
Clin Epigenetics; 2016; 8():98. PubMed ID: 27651838
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics of prostate cancer: beyond DNA methylation.
Schulz WA; Hatina J
J Cell Mol Med; 2006; 10(1):100-25. PubMed ID: 16563224
[TBL] [Abstract][Full Text] [Related]
19. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.
Bianco-Miotto T; Chiam K; Buchanan G; Jindal S; Day TK; Thomas M; Pickering MA; O'Loughlin MA; Ryan NK; Raymond WA; Horvath LG; Kench JG; Stricker PD; Marshall VR; Sutherland RL; Henshall SM; Gerald WL; Scher HI; Risbridger GP; Clements JA; Butler LM; Tilley WD; Horsfall DJ; Ricciardelli C;
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2611-22. PubMed ID: 20841388
[TBL] [Abstract][Full Text] [Related]
20. Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia.
Paradowska A; Fenic I; Konrad L; Sturm K; Wagenlehner F; Weidner W; Steger K
Int J Oncol; 2009 Jul; 35(1):87-96. PubMed ID: 19513555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
